Rock Creek Pharmaceuticals, Inc., a subsidiary of Star Scientific, Inc. (NASDAQ: CIGX), announced that PGA Tour professional, Fred Couples, is the company’s first Brand Ambassador for Anatabloc™, its breakthrough product for anti-inflammatory support. Couples is a 32-year veteran of the PGA Tour, with over 50 professional tournament
wins including the Masters (1992), and has been twice named the PGA Tour
Player of the Year (1991, 1992).
“I started taking Anatabloc™, and within a few days, I simply started feeling better,” said Couples. “There has been a difference in how I feel, both when I wake up in the morning and throughout my day. Anatabloc™ was an amazing find for me and I continue to feel better.”
Introduced in August 2011, Anatabloc™ is a dietary supplement that assists
the body’s natural process for regulating inflammation using an alkaloid
found in plants and vegetables, combined with Vitamins A and D3 to assist
in maintaining healthy levels of inflammation. Excessive inflammation is
associated with a variety of autoimmune conditions, as well as athletic and
work-out injuries. Anatabloc™ is now available through GNC.com.
“We discovered from golf legend Fred Couples that he had been taking Anatabloc™ and we were delighted to hear he was feeling great and seeinreal results,” said David Dean, Vice President, Sales and Marketing, Star
Scientific. “Given his stature and popularity on and off the course, it made absolute sense to ask him to join our team as a Brand Ambassador. This year marks the 20th anniversary of Couples’ win at the Masters and he will
be playing in the Tournament. To be in the game at this level and playing this long is an amazing accomplishment.” Dean added.
Couples will wear the Anatabloc™ logo on his sleeve at all tournaments going forward.
Couples announced his partnership with Anatabloc™ and his use of the anti-inflammatory supplement at the Northern Trust Open—a tournament he almost won in 2011—at the Riviera Country Club in Pacific Palisades, CA.
“Anatabloc™ should enable millions of Americans, like Fred, to be more active by maintaining a healthy level of inflammation,” said Jonnie Williams Sr., Chief Executive Officer, Star Scientific. “Other professional athletes such as NFL All-Star Jeremy Shockey and tennis stars Jimmy Arias, Aaron Krickstein, Rob Seguso and legendary coach Nick Bollettierri are already using Anatabloc™ and talking about how it is changing their careers as well. We want everyone to know there is a new way to deal with the aches and pains associated with excessive inflammation, and the answer is Anatabloc™,” he added.
“I hope my story will let millions of Americans know that Anatabloc™ may be an answer in helping them return to an active lifestyle,” said Couples. Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such
as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and
are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to,
the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceuticals, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, including with respect to our
nutraceuticals, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31,
2010. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.